|Bid||9.00 x 1200|
|Ask||14.25 x 1300|
|Day's range||12.90 - 13.21|
|52-week range||12.64 - 23.25|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||2.74|
|Earnings date||03 May 2023 - 08 May 2023|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||07 Oct 2008|
|1y target est||21.17|
CHICAGO, March 23, 2023--Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Allergy and Immunology and second for Rheumatology within its 2023 Ambulatory EHR by Physician Specialty category.
CHICAGO, March 22, 2023--Veradigm Inc. (NASDAQ: MDRX), announced today an update on the status of its year-end audit procedures for 2022. As the Company disclosed on February 28, 2023, due to an expansion of year-end audit procedures, the Company filed with the SEC a Form 12b-25, extending the due date of its annual report on Form 10-K by 15 days, to allow for completion of those procedures.
Veradigm Inc. ( NASDAQ:MDRX ) shareholders might be concerned after seeing the share price drop 26% in the last...